<article title='Bacteriophage'><paragraph><template><target>Redirect</target><arg>Phage</arg></template><template><target>Use dmy dates</target><arg name="date">July 2012</arg></template><link><target>File:PhageExterior.svg</target><part>right</part><part>thumb</part><part>The structure of a typical myovirus bacteriophage</part></link></paragraph><paragraph>A<space/><bold>bacteriophage</bold><space/><template><target>IPAc-en</target><arg>'</arg><arg>b</arg><arg>æ</arg><arg>k</arg><arg>ˈ</arg><arg>t</arg><arg>ɪəɹ</arg><arg>.</arg><arg>i</arg><arg>.</arg><arg>əʊ</arg><arg>ˌ</arg><arg>f</arg><arg>eɪ</arg><arg>dʒ</arg></template><space/>(informally,<space/><italics>phage</italics><space/><template><target>IPAc-en</target><arg>'</arg><arg>f</arg><arg>eɪ</arg><arg>dʒ</arg></template>) is a<space/><link><target>virus</target></link><space/>that infects and replicates within a<space/><link><target>bacterium</target></link>. The term is derived from &quot;bacteria&quot; and the<space/><template><target>lang-el</target><arg>φαγεῖν</arg></template><space/>(<italics>phagein</italics>), &quot;to devour&quot;. Bacteriophages are composed of<space/><link><target>protein</target><trail>s</trail></link><space/>that<space/><link><target>Capsid</target><part>encapsulate</part></link><space/>a<space/><link><target>DNA</target></link><space/>or<space/><link><target>RNA</target></link><space/><link><target>genome</target></link>, and may have relatively simple or elaborate structures. Their genomes may encode<space/><link><target>Bacteriophage MS2</target><part>as few as four</part></link><space/>genes, and as many as hundreds of<space/><link><target>genes</target></link>. Phages replicate within the bacterium following the injection of their genome into its<space/><link><target>cytoplasm</target></link>. Bacteriophages are among the most common and diverse entities in the<space/><link><target>biosphere</target></link>.<extension extension_name='ref' name="autogenerated1"><template><target>cite book</target><arg name="author"><space/>Mc Grath S and van Sinderen D (editors).<space/></arg><arg name="title"><space/>Bacteriophage: Genetics and Molecular Biology<space/></arg><arg name="edition"><space/>1st<space/></arg><arg name="publisher"><space/>Caister Academic Press<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="url">http://www.horizonpress.com/phage<space/></arg><arg name="id"><space/>[http://www.horizonpress.com/phage]<space/></arg><arg name="isbn"><space/>978-1-904455-14-1</arg></template></extension></paragraph><paragraph>Phages are widely distributed in locations populated by<space/><link><target>bacteria</target><trail>l</trail></link><space/>hosts, such as soil or the intestines of animals. One of the densest natural sources for phages and other viruses is sea water, where up to 910<xhtml:sup>8</xhtml:sup><space/><link><target>virus</target><part>virions</part></link><space/>per milliliter have been found in microbial mats at the surface,<extension extension_name='ref' name="mmbr"><template><target>Cite journal</target><arg name="last1"><space/>Wommack<space/></arg><arg name="first1"><space/>K. E.<space/></arg><arg name="last2"><space/>Colwell<space/></arg><arg name="first2"><space/>R. R.<space/></arg><arg name="doi"><space/>10.1128/MMBR.64.1.69-114.2000<space/></arg><arg name="title"><space/>Virioplankton: Viruses in Aquatic Ecosystems<space/></arg><arg name="journal"><space/>Microbiology and Molecular Biology Reviews<space/></arg><arg name="volume"><space/>64<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>69–114<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pmid"><space/>10704475</arg><arg name="pmc">98987<space/></arg></template></extension><space/>and up to 70% of marine bacteria may be infected by phages.<extension extension_name='ref' name="Prescott">Prescott, L. (1993). Microbiology, Wm. C. Brown Publishers, ISBN 0-697-01372-3</extension>They have been used for over 90 years as an alternative to antibiotics in the former<space/><link><target>Soviet Union</target></link><space/>and Central Europe, as well as in France.<extension extension_name='ref' name="horizon">BBC Horizon (1997):<space/><italics>The Virus that Cures</italics><space/>Documentary about the history of phage medicine in Russia and the West</extension><space/>They are seen as a possible therapy against<space/><link><target>multi-drug-resistant</target></link><space/>strains of many bacteria (see<space/><link><target>phage therapy</target></link>).<extension extension_name='ref' name="fmicb"><template><target>Cite journal</target><arg name="last1"><space/>Keen<space/></arg><arg name="first1"><space/>E. C.<space/></arg><arg name="title"><space/>Phage Therapy: Concept to Cure<space/></arg><arg name="doi"><space/>10.3389/fmicb.2012.00238<space/></arg><arg name="journal"><space/>Frontiers in Microbiology<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22833738</arg><arg name="pmc"><space/>3400130</arg></template></extension></paragraph><heading level='2'>Classification</heading><paragraph>Bacteriophages occur abundantly in the biosphere, with different virions, genomes and lifestyles. Phages are classified by the<space/><link><target>International Committee on Taxonomy of Viruses</target></link><space/>(ICTV) according to morphology and nucleic acid.</paragraph><paragraph>Nineteen families are currently recognized by the ICTV that infect<space/><link><target>bacteria</target></link><space/>and<space/><link><target>archaea</target></link>. Of these, only two families have RNA genomes and only five families are enveloped. Of the viral families with DNA genomes, only two have single-stranded genomes. Eight of the viral families with DNA genomes have circular genomes, while nine have linear genomes. Nine families infect bacteria only, nine infect<space/><link><target>archaea</target></link><space/>only, and one (<italics>Tectiviridae</italics>) infects both bacteria and archaea.</paragraph><table class="wikitable sortable"><tablecaption><bold>ICTV classification of prokaryotic (bacterial and archaeal) viruses</bold><extension extension_name='ref' name="autogenerated1"></extension></tablecaption><tablerow style="background:gray;"><tablehead>Order</tablehead><tablehead>Family</tablehead><tablehead>Morphology</tablehead><tablehead>Nucleic acid</tablehead><tablehead>Examples</tablehead></tablerow><tablerow><tablecell rowspan="3"><italics><link><target>Caudovirales</target></link></italics></tablecell><tablecell><italics><link><target>Myoviridae</target></link></italics></tablecell><tablecell>Non<link><target>Viral envelope</target><part>enveloped</part></link>, contractile tail</tablecell><tablecell>Linear dsDNA</tablecell><tablecell><link><target>T4 phage</target></link>,<space/><link><target>Mu phage</target><part>Mu</part></link>, PBSX, P1Puna-like, P2, I3, Bcep 1, Bcep 43, Bcep 78</tablecell></tablerow><tablerow><tablecell><italics><link><target>Siphoviridae</target></link></italics></tablecell><tablecell>Nonenveloped, noncontractile tail (long)</tablecell><tablecell>Linear dsDNA</tablecell><tablecell><link><target>Lambda phage</target><part>phage</part></link>,<space/><link><target>Bacteriophage T5</target><part>T5 phage</part></link>, phi, C2, L5,<space/><link><target>HK97</target></link>, N15</tablecell></tablerow><tablerow><tablecell><italics><link><target>Podoviridae</target></link></italics></tablecell><tablecell>Nonenveloped, noncontractile tail (short)</tablecell><tablecell>Linear dsDNA</tablecell><tablecell><link><target>T7 phage</target></link>,<space/><link><target>T3 phage</target></link>, P22, P37</tablecell></tablerow><tablerow><tablecell rowspan="2"><italics><link><target>Ligamenvirales</target></link></italics></tablecell><tablecell><italics><link><target>Lipothrixviridae</target></link></italics></tablecell><tablecell>Enveloped, rod-shaped</tablecell><tablecell>Linear dsDNA</tablecell><tablecell><link><target>Acidianus filamentous virus 1</target></link></tablecell></tablerow><tablerow><tablecell><italics><link><target>Rudiviridae</target></link></italics></tablecell><tablecell>Nonenveloped, rod-shaped</tablecell><tablecell>Linear dsDNA</tablecell><tablecell><link><target>Sulfolobus islandicus rod-shaped virus 1</target></link></tablecell></tablerow><tablerow><tablecell rowspan="26">Unassigned</tablecell><tablecell><italics><link><target>Ampullaviridae</target></link></italics></tablecell><tablecell>Enveloped, bottle-shaped</tablecell><tablecell>Linear dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Bicaudaviridae</target></link></italics></tablecell><tablecell>Nonenveloped, lemon-shaped</tablecell><tablecell>Circular dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Clavaviridae</target></link></italics></tablecell><tablecell>Nonenveloped, rod-shaped</tablecell><tablecell>Circular dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Corticoviridae</target></link></italics></tablecell><tablecell>Nonenveloped, isometric</tablecell><tablecell>Circular dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Cystoviridae</target></link></italics></tablecell><tablecell>Enveloped, spherical</tablecell><tablecell>Segmented dsRNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Fuselloviridae</target></link></italics></tablecell><tablecell>Nonenveloped, lemon-shaped</tablecell><tablecell>Circular dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Globuloviridae</target></link></italics></tablecell><tablecell>Enveloped, isometric</tablecell><tablecell>Linear dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Guttaviridae</target></link></italics></tablecell><tablecell>Nonenveloped, ovoid</tablecell><tablecell>Circular dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Inoviridae</target></link></italics></tablecell><tablecell>Nonenveloped, filamentous</tablecell><tablecell>Circular ssDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Leviviridae</target></link></italics></tablecell><tablecell>Nonenveloped, isometric</tablecell><tablecell>Linear ssRNA</tablecell><tablecell><link><target>Bacteriophage MS2</target><part>MS2</part></link>,<space/><link><target>Bacteriophage Q</target><part>Q</part></link></tablecell></tablerow><tablerow><tablecell><italics><link><target>Microviridae</target></link></italics></tablecell><tablecell>Nonenveloped, isometric</tablecell><tablecell>Circular ssDNA</tablecell><tablecell><link><target>Phi X 174</target><part>X174</part></link></tablecell></tablerow><tablerow><tablecell><italics><link><target>Plasmaviridae</target></link></italics></tablecell><tablecell>Enveloped, pleomorphic</tablecell><tablecell>Circular dsDNA</tablecell><tablecell></tablecell></tablerow><tablerow><tablecell><italics><link><target>Tectiviridae</target></link></italics></tablecell><tablecell>Nonenveloped, isometric</tablecell><tablecell>Linear dsDNA</tablecell><tablecell></tablecell></tablerow></table><heading level='2'>History</heading><paragraph>Since ancient times, reports of river waters having the ability to cure infectious diseases, such as<space/><link><target>leprosy</target></link>, have been documented. In 1896,<space/><link><target>Ernest Hanbury Hankin</target></link><space/>reported that something in the waters of the<space/><link><target>Ganges</target></link><space/>and<space/><link><target>Yamuna</target></link><space/>rivers in<space/><link><target>India</target></link><space/>had marked<space/><link><target>antibacterial</target></link><space/>action against<space/><link><target>cholera</target></link><space/>and could pass through a very fine porcelain filter. In 1915,<space/><link><target>United Kingdom</target><part>British</part></link><space/><link><target>bacteriologist</target></link><space/><link><target>Frederick Twort</target></link>, superintendent of the Brown Institution of London, discovered a small agent that infected and killed bacteria. He believed the agent must be one of the following:</paragraph><list type='numbered'><listitem>a stage in the<space/><link><target>Biological life cycle</target><part>life cycle</part></link><space/>of the bacteria;</listitem><listitem>an<space/><link><target>enzyme</target></link><space/>produced by the bacteria themselves; or</listitem><listitem>a virus that grew on and destroyed the bacteria.</listitem></list><paragraph>Twort's work was interrupted by the onset of<space/><link><target>World War I</target></link><space/>and shortage of funding. Independently,<space/><link><target>French-Canadian</target></link><space/><link><target>microbiology</target><part>microbiologist</part></link><space/><link><target>Flix d'Hrelle</target></link>, working at the<space/><link><target>Pasteur Institute</target></link><space/>in<space/><link><target>Paris</target></link>, announced on 3 September 1917, that he had discovered &quot;an invisible, antagonistic microbe of the<space/><link><target>dysentery</target></link><space/>bacillus&quot;. For dHrelle, there was no question as to the nature of his discovery: &quot;In a flash I had understood: what caused my clear spots was in fact an invisible microbe a virus parasitic on bacteria.&quot;<extension extension_name='ref' name="Herelle1917"><template><target>cite journal</target><arg name="author"><space/>Félix d'Hérelles
</arg><arg name="year"><space/>1917
</arg><arg name="title"><space/>Sur un microbe invisible antagoniste des bacilles dysentériques
</arg><arg name="journal"><space/>Comptes rendus Acad Sci Paris.
</arg><arg name="volume"><space/>165
</arg><arg name="pages"><space/>373–5
</arg><arg name="url"><space/>http://202.114.65.51/fzjx/wsw/wswfzjs/pdf/1917p157.pdf
</arg><arg name="archiveurl"><space/>http://www.webcitation.org/5uicsPk41
</arg><arg name="archivedate"><space/>4 December 2010
</arg><arg name="format"><space/>PDF
</arg><arg name="accessdate">5 September 2010
</arg></template></extension><space/>D'Hrelle called the virus a bacteriophage or bacteria-eater (from the Greek<space/><italics>phagein</italics><space/>meaning to eat). He also recorded a dramatic account of a man suffering from dysentery who was restored to good health by the bacteriophages.<extension extension_name='ref' name="Herelle1949"><template><target>cite journal</target><arg name="author"><space/>Félix d'Hérelle
</arg><arg name="year"><space/>1949
</arg><arg name="title"><space/>The bacteriophage
</arg><arg name="journal"><space/>Science News
</arg><arg name="volume"><space/>14
</arg><arg name="pages"><space/>44–59
</arg><arg name="url"><space/>http://mmbr.asm.org/cgi/reprint/40/4/793.pdf
</arg><arg name="format"><space/>PDF
</arg><arg name="accessdate">5 September 2010
</arg></template></extension><space/>It was D'Herelle who conducted much research into bacteriophages and introduced the concept of<space/><link><target>phage therapy</target></link>.<extension extension_name='ref' name="Keen"><template><target>cite journal</target><arg name="author">Keen EC
</arg><arg name="title">Felix d’Herelle and Our Microbial Future
</arg><arg name="journal">Future Microbiology
</arg><arg name="volume">7
</arg><arg name="issue">12
</arg><arg name="pages">1337–1339
</arg><arg name="year">2012
</arg><arg name="pmid">23231482
</arg><arg name="doi">10.2217/fmb.12.115
</arg></template></extension></paragraph><paragraph>In 1969,<space/><link><target>Delbrck, Max Ludwig Henning</target><part>Max Delbrck</part></link>,<space/><link><target>Alfred Hershey</target></link><space/>and<space/><link><target>Luria, S. E.</target><part>Salvador Luria</part></link><space/>were awarded the<space/><link><target>Nobel Prize in Physiology and Medicine</target></link><space/>for their discoveries of the replication of viruses and their genetic structure.<extension extension_name='ref' name="nobel-1969"><template><target>cite web</target><arg name="url"><space/>http://nobelprize.org/nobel_prizes/medicine/laureates/1969/index.html
</arg><arg name="title"><space/>The Nobel Prize in Physiology or Medicine 1969
</arg><arg name="accessdate"><space/>2007-07-28
</arg><arg name="publisher"><space/>Nobel Foundation
</arg></template></extension></paragraph><heading level='2'>Phage therapy</heading><paragraph><template><target>Main</target><arg>Phage therapy</arg></template></paragraph><paragraph>Phages were discovered to be antibacterial agents and were used in the former<space/><link><target>Soviet</target></link><space/>Republic of<space/><link><target>Georgia (country)</target><part>Georgia</part></link><space/>(pioneered there by<space/><link><target>Giorgi Eliava</target></link><space/>with help from the co-discoverer of bacteriophages, Felix d'Herelle) and the<space/><link><target>United States</target></link><space/>during the 1920s and 1930s for treating bacterial infections. They had widespread use, including treatment of soldiers in the Red Army. However, they were abandoned for general use in the West for several reasons:</paragraph><list type='bullet'><listitem>Medical trials were carried out, but a basic lack of understanding of phages made these invalid.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Kutter</arg><arg name="first1">Elizabeth</arg><arg name="last2">De Vos</arg><arg name="first2">Daniel</arg><arg name="last3">Gvasalia</arg><arg name="first3">Guram</arg><arg name="last4">Alavidze</arg><arg name="first4">Zemphira</arg><arg name="last5">Gogokhia</arg><arg name="first5">Lasha</arg><arg name="last6">Kuhl</arg><arg name="first6">Sarah</arg><arg name="last7">Abedon</arg><arg name="first7">Stephen</arg><arg name="title">Phage Therapy in Clinical Practice: Treatment of Human Infections</arg><arg name="journal">Current Pharmaceutical Biotechnology</arg><arg name="date">1 January 2010</arg><arg name="volume">11</arg><arg name="issue">1</arg><arg name="pages">69–86</arg><arg name="doi">10.2174/138920110790725401</arg><arg name="pmid">20214609</arg></template></extension></listitem><listitem>Antibiotics were discovered and marketed widely. They were easier to make, store and to prescribe.</listitem><listitem>Former Soviet research continued, but publications were mainly in Russian or Georgian languages, and were unavailable internationally for many years.</listitem><listitem>Clinical trials evaluating the antibacterial efficacy of bacteriophage preparations were conducted without proper controls and were methodologically incomplete preventing the formulation of important conclusions.<template><target>citation needed</target><arg name="date">October 2014</arg></template></listitem></list><paragraph>Their use has continued since the end of the Cold War in Georgia and elsewhere in Central and Eastern Europe. Globalyz Biotech is an international joint venture that commercializes bacteriophage treatment and its various applications across the globe. The company has successfully used bacteriophages in administering<space/><link><target>Phage therapy</target></link><space/>to patients suffering from bacterial infections, including:<space/><link><target>Staphylococcus</target></link><space/>(including<space/><link><target>Methicillin-resistant Staphylococcus aureus</target><part>MRSA</part></link>),<space/><link><target>Streptococcus</target></link>,<space/><link><target>Pseudomonas</target></link>,<space/><link><target>Salmonella</target></link>, skin and soft tissue, gastrointestinal, respiratory, and orthopedic infections. In 1923, the<space/><link><target>George Eliava Institute</target><part>Eliava Institute</part></link><space/>was opened in<space/><link><target>Tbilisi, Georgia</target></link>, to research this new science and put it into practice.</paragraph><paragraph>The first regulated randomized, double blind clinical trial was reported in the Journal of Wound Care in June 2009, which evaluated the safety and efficacy of a bacteriophage cocktail to treat infected venous leg ulcers in human patients. The study was approved by the FDA as a Phase I clinical trial. Study results satisfactorily demonstrated safety of therapeutic application of bacteriophages, however it did not show efficacy. The authors explain that the use of certain chemicals that are part of standard wound care (e.g. lactoferrin, silver) may have interfered with bacteriophage viability. Another regulated clinical trial in Western Europe (treatment of ear infections caused by<space/><italics>Pseudomonas aeruginosa</italics>) was reported shortly after in the journal Clinical Otolaryngology in August 2009.[14] The study concludes that bacteriophage preparations were safe and effective for treatment of chronic ear infections in humans. Additionally, there have been numerous animal and other experimental clinical trials evaluating the efficacy of bacteriophages for various diseases, such as infected burns and wounds, and cystic fibrosis associated lung infections, among others. Meanwhile, Western scientists are developing engineered viruses to overcome antibiotic resistance, and engineering the phage genes responsible for coding enzymes which degrade the biofilm matrix, phage structural proteins and also enzymes responsible for lysis of bacterial cell wall.<extension extension_name='ref' name="mmbr"></extension><extension extension_name='ref' name="Prescott"></extension><extension extension_name='ref' name="horizon"></extension></paragraph><paragraph>D'Herelle &quot;quickly learned that bacteriophages are found wherever bacteria thrive: in sewers, in rivers that catch waste runoff from pipes, and in the stools of convalescent patients.&quot;<extension extension_name='ref'><template><target>Citation</target><arg name="last"><space/>Kuchment<space/></arg><arg name="first"><space/>Anna<space/></arg><arg name="year"><space/>2012
</arg><arg name="title"><space/>The Forgotten Cure: The past and future of phage therapy<space/></arg><arg name="publisher"><space/>Springer<space/></arg><arg name="page"><space/>11
</arg><arg name="isbn"><space/>978-1-4614-0250-3</arg></template></extension><space/>This includes rivers traditionally thought to have healing powers, including India's<space/><link><target>Ganges</target></link><space/>River.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Deresinski</arg><arg name="first">Stan</arg><arg name="title">Bacteriophage Therapy: Exploiting Smaller Fleas</arg><arg name="journal">Clinical Infectious Diseases</arg><arg name="date">15 April 2009</arg><arg name="volume">48</arg><arg name="issue">8</arg><arg name="pages">1096–1101</arg><arg name="doi">10.1086/597405</arg></template></extension></paragraph><heading level='2'>Replication</heading><paragraph><link><target>File:Phage injection.png</target><part>thumb</part><part>right</part><part>Diagram of the DNA injection process</part></link>Bacteriophages may have a<space/><link><target>lytic cycle</target></link><space/>or a<space/><link><target>lysogenic cycle</target></link>, and a few viruses are capable of carrying out both. With<space/><italics>lytic phages</italics><space/>such as the<space/><link><target>T4 phage</target></link>, bacterial cells are broken open (lysed) and destroyed after immediate replication of the virion. As soon as the cell is destroyed, the phage progeny can find new hosts to infect. Lytic phages are more suitable for<space/><link><target>phage therapy</target></link>. Some lytic phages undergo a phenomenon known as lysis inhibition, where completed phage progeny will not immediately lyse out of the cell if extracellular phage concentrations are high. This mechanism is not identical to that of<space/><link><target>Temperateness (virology)</target><part>temperate phage</part></link><space/>going dormant and is usually temporary.</paragraph><paragraph>In contrast, the<space/><italics><link><target>lysogenic cycle</target></link></italics><space/>does not result in immediate lysing of the host cell. Those phages able to undergo lysogeny are known as<space/><link><target>temperate phage</target><trail>s</trail></link>. Their viral genome will integrate with host DNA and replicate along with it fairly harmlessly, or may even become established as a<space/><link><target>plasmid</target></link>. The virus remains dormant until host conditions deteriorate, perhaps due to depletion of nutrients; then, the<space/><link><target>endogenous</target></link><space/>phages (known as<space/><link><target>prophage</target><trail>s</trail></link>) become active. At this point they initiate the reproductive cycle, resulting in lysis of the host cell. As the lysogenic cycle allows the host cell to continue to survive and reproduce, the virus is reproduced in all of the cells offspring.An example of a bacteriophage known to follow the lysogenic cycle and the lytic cycle is the phage lambda of<space/><italics>E. coli.</italics><extension extension_name='ref'>Mason, Kenneth A., Jonathan B. Losos, Susan R. Singer, Peter H Raven, and George B. Johnson. (2011).<space/><italics>Biology</italics>, p. 533. McGraw-Hill, New York. ISBN 978-0-07-893649-4.</extension></paragraph><paragraph>Sometimes prophages may provide benefits to the host bacterium while they are dormant by adding new functions to the bacterial<space/><link><target>genome</target></link><space/>in a phenomenon called<space/><link><target>lysogenic conversion</target></link>. Examples are the conversion of harmless strains of<space/><italics><link><target>Corynebacterium diphtheriae</target></link></italics><space/>or<space/><italics><link><target>Vibrio cholerae</target></link></italics><space/>by bacteriophages to highly virulent ones, which cause<space/><link><target>Diphtheria</target></link><space/>or<space/><link><target>cholera</target></link>, respectively.<extension extension_name='ref' name="pmid19007916"><template><target>cite journal</target><arg name="author">Mokrousov I<space/></arg><arg name="title">Corynebacterium diphtheriae: genome diversity, population structure and genotyping perspectives<space/></arg><arg name="journal">Infection, Genetics and Evolution<space/></arg><arg name="volume">9<space/></arg><arg name="issue">1<space/></arg><arg name="pages">1–15<space/></arg><arg name="date">January 2009<space/></arg><arg name="pmid">19007916<space/></arg><arg name="doi">10.1016/j.meegid.2008.09.011<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid21799407"><template><target>cite journal</target><arg name="author">Charles RC, Ryan ET<space/></arg><arg name="title">Cholera in the 21st century<space/></arg><arg name="journal">Current Opinion in Infectious Diseases<space/></arg><arg name="volume">24<space/></arg><arg name="issue">5<space/></arg><arg name="pages">472–7<space/></arg><arg name="date">October 2011<space/></arg><arg name="pmid">21799407<space/></arg><arg name="doi">10.1097/QCO.0b013e32834a88af<space/></arg><arg name="url"></arg></template></extension><space/>Strategies to combat certain bacterial infections by targeting these toxin-encoding prophages have been proposed.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Keen<space/></arg><arg name="first1"><space/>E. C.<space/></arg><arg name="title"><space/>Paradigms of pathogenesis: Targeting the mobile genetic elements of disease<space/></arg><arg name="doi"><space/>10.3389/fcimb.2012.00161<space/></arg><arg name="journal"><space/>Frontiers in Cellular and Infection Microbiology<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="page">161</arg><arg name="date"><space/>December 2012<space/></arg><arg name="pmid"><space/>23248780</arg><arg name="pmc"><space/>3522046</arg></template></extension></paragraph><heading level='3'>Attachment and penetration</heading><paragraph><link><target>File:Phage.jpg</target><part>thumb</part><part>In this<space/><link><target>electron micrograph</target></link><space/>of bacteriophages attached to a bacterial cell, the viruses are the size and shape of coliphage T1.</part></link></paragraph><preblock><preline>To enter a host cell, bacteriophages attach to specific receptors on the surface of bacteria, including<space/><link><target>lipopolysaccharide</target><trail>s</trail></link>,<space/><link><target>teichoic acid</target><trail>s</trail></link>,<space/><link><target>protein</target><trail>s</trail></link>, or even<space/><link><target>flagella</target></link>. This specificity means a bacteriophage can infect only certain bacteria bearing receptors to which they can bind, which in turn determines the phage's host range. Host growth conditions also influence the ability of the phage to attach and invade them.<extension extension_name='ref' name="pmid9356254"><template><target>Cite journal</target><arg name="last1"><space/>Gabashvili<space/></arg><arg name="first1"><space/>I. 
</arg><arg name="last2"><space/>Khan<space/></arg><arg name="first2"><space/>S. 
</arg><arg name="last3"><space/>Hayes<space/></arg><arg name="first3"><space/>S. 
</arg><arg name="last4"><space/>Serwer<space/></arg><arg name="first4"><space/>P. 
</arg><arg name="title"><space/>Polymorphism of bacteriophage T7 
</arg><arg name="doi"><space/>10.1006/jmbi.1997.1353 
</arg><arg name="journal"><space/>Journal of Molecular Biology 
</arg><arg name="volume"><space/>273 
</arg><arg name="issue"><space/>3 
</arg><arg name="pages"><space/>658–67 
</arg><arg name="year"><space/>1997 
</arg><arg name="pmid"><space/>
9356254</arg><arg name="pmc"><space/>
</arg></template></extension><space/>As phage virions do not move independently, they must rely on random encounters with the right receptors when in solution (blood, lymphatic circulation, irrigation, soil water, etc.).</preline></preblock><paragraph>Myovirus bacteriophages use a<space/><link><target>hypodermic syringe</target></link>-like motion to inject their genetic material into the cell. After making contact with the appropriate receptor, the tail fibers flex to bring the base plate closer to the surface of the cell; this is known as reversible binding. Once attached completely, irreversible binding is initiated and the tail contracts, possibly with the help of<space/><link><target>Adenosine triphosphate</target><part>ATP</part></link><space/>present in the tail,<extension extension_name='ref' name="Prescott"></extension><space/>injecting genetic material through the bacterial membrane.Podoviruses lack an elongated tail sheath similar to that of a myovirus, so they instead use their small, tooth-like tail fibers to enzymatically degrade a portion of the cell membrane before inserting their genetic material.</paragraph><heading level='3'>Synthesis of proteins and nucleic acid</heading><paragraph>Within minutes, bacterial<space/><link><target>ribosome</target><trail>s</trail></link><space/>start translating viral mRNA into protein. For RNA-based phages,<space/><link><target>RNA replicase</target></link><space/>is synthesized early in the process. Proteins modify the bacterial<space/><link><target>RNA polymerase</target></link><space/>so it preferentially transcribes viral mRNA. The hosts normal synthesis of proteins and nucleic acids is disrupted, and it is forced to manufacture viral products instead. These products go on to become part of new virions within the cell, helper proteins that help assemble the new virions, or proteins involved in cell<space/><link><target>lysis</target></link>.<space/><link><target>Walter Fiers</target></link><space/>(<link><target>University of Ghent</target></link>,<space/><link><target>Belgium</target></link>) was the first to establish the complete nucleotide sequence of a gene (1972) and of the viral genome of<space/><link><target>bacteriophage MS2</target></link><space/>(1976).<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Fiers<space/></arg><arg name="first1"><space/>W. 
</arg><arg name="last2"><space/>Contreras<space/></arg><arg name="first2"><space/>R. 
</arg><arg name="last3"><space/>Duerinck<space/></arg><arg name="first3"><space/>F. 
</arg><arg name="last4"><space/>Haegeman<space/></arg><arg name="first4"><space/>G. 
</arg><arg name="last5"><space/>Iserentant<space/></arg><arg name="first5"><space/>D. 
</arg><arg name="last6"><space/>Merregaert<space/></arg><arg name="first6"><space/>J. 
</arg><arg name="last7"><space/>Min Jou<space/></arg><arg name="first7"><space/>W. 
</arg><arg name="last8"><space/>Molemans<space/></arg><arg name="first8"><space/>F. 
</arg><arg name="last9"><space/>Raeymaekers<space/></arg><arg name="first9"><space/>A. 
</arg><arg name="doi"><space/>10.1038/260500a0 
</arg><arg name="last10"><space/>Van Den Berghe<space/></arg><arg name="first10"><space/>A. 
</arg><arg name="last11"><space/>Volckaert<space/></arg><arg name="first11"><space/>G. 
</arg><arg name="last12"><space/>Ysebaert<space/></arg><arg name="first12"><space/>M. 
</arg><arg name="title"><space/>Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene 
</arg><arg name="journal"><space/>Nature 
</arg><arg name="volume"><space/>260 
</arg><arg name="issue"><space/>5551 
</arg><arg name="pages"><space/>500–507 
</arg><arg name="year"><space/>1976 
</arg><arg name="pmid"><space/>1264203</arg><arg name="pmc"><space/>
</arg><arg name="bibcode"><space/>1976Natur.260..500F<space/></arg></template></extension></paragraph><heading level='3'>Virion assembly</heading><paragraph>In the case of the<space/><link><target>T4 phage</target></link>, the construction of new virus particles involves the assistance of helper proteins. The base plates are assembled first, with the tails being built upon them afterwards. The head capsids, constructed separately, will spontaneously assemble with the tails. The DNA is packed efficiently within the heads. The whole process takes about 15 minutes.<link><target>File:Tevenphage.svg</target><part>thumb</part><part>right</part><part>300px</part><part>Diagram of a typical tailed bacteriophage structure</part></link></paragraph><heading level='3'>Release of virions</heading><paragraph>Phages may be released via cell lysis, by extrusion, or, in a few cases, by budding. Lysis, by tailed phages, is achieved by an enzyme called<space/><link><target>endolysin</target></link>, which attacks and breaks down the cell wall<space/><link><target>peptidoglycan</target></link>. An altogether different phage type, the filamentous phages, make the host cell continually secrete new virus particles. Released virions are described as free, and, unless defective, are capable of infecting a new bacterium. Budding is associated with certain<space/><italics><link><target>Mycoplasma</target></link></italics><space/>phages. In contrast to virion release, phages displaying a<space/><link><target>lysogenic</target></link><space/>cycle do not kill the host but, rather, become long-term residents as<space/><link><target>prophage</target></link>.</paragraph><heading level='2'>Genome structure</heading><paragraph>Bacteriophage genomes are especially mosaic: the genome of any one phage species appears to be composed of numerous individual modules. These modules may be found in other phage species in different arrangements.<space/><link><target>Mycobacteriophages</target></link><space/>bacteriophages with<space/><link><target>mycobacteria</target><trail>l</trail></link><space/>hosts have provided excellent examples of this mosaicism. In these mycobacteriophages, genetic assortment may be the result of repeated instances of<space/><link><target>site-specific recombination</target></link><space/>and illegitimate recombination (the result of phage genome acquisition of bacterial host genetic sequences).<extension extension_name='ref' name="pmid18178732"><template><target>cite journal</target><arg name="author">Morris P, Marinelli LJ, Jacobs-Sera D, Hendrix RW, Hatfull GF<space/></arg><arg name="title">Genomic characterization of mycobacteriophage Giles: evidence for phage acquisition of host DNA by illegitimate recombination<space/></arg><arg name="journal">Journal of Bacteriology<space/></arg><arg name="volume">190<space/></arg><arg name="issue">6<space/></arg><arg name="pages">2172–82<space/></arg><arg name="date">March 2008<space/></arg><arg name="pmid">18178732<space/></arg><arg name="pmc">2258872<space/></arg><arg name="doi">10.1128/JB.01657-07<space/></arg><arg name="url">http://jb.asm.org/cgi/pmidlookup?view</arg></template></extension><space/>It should be noted, however, that evolutionary mechanisms shaping the genomes of bacterial viruses vary between different families and depend on the type of the nucleic acid, characteristics of the virion structure, as well as the mode of the viral life cycle.<extension extension_name='ref' name="pmid22126996"><template><target>cite journal</target><arg name="author">Krupovic M, Prangishvili D, Hendrix RW, Bamford DH<space/></arg><arg name="title">Genomics of bacterial and archaeal viruses: dynamics within the prokaryotic virosphere<space/></arg><arg name="journal">Microbiology and Molecular Biology Reviews : MMBR<space/></arg><arg name="volume">75<space/></arg><arg name="issue">4<space/></arg><arg name="pages">610–35<space/></arg><arg name="date">December 2011<space/></arg><arg name="pmid">22126996<space/></arg><arg name="pmc">3232739<space/></arg><arg name="doi">10.1128/MMBR.00011-11<space/></arg><arg name="url">http://mmbr.asm.org/cgi/pmidlookup?view</arg></template></extension></paragraph><heading level='2'>In the environment</heading><paragraph><template><target>Main</target><arg>Marine bacteriophage</arg></template><link><target>Metagenomics</target></link><space/>has allowed the in-water detection of bacteriophages that was not possible previously.<extension extension_name='ref'>Breitbart, M, P Salamon, B Andresen, J Mahaffy, A Segall, D Mead, F Azam, F Rohwer (2002) Genomic analysis of uncultured marine viral communities. Proceedings of the National Academy USA. 99:14250-14255.</extension></paragraph><paragraph>Bacteriophages have also been used in<space/><link><target>hydrology</target><part>hydrological</part></link><space/>tracing and modelling in<space/><link><target>river</target></link><space/>systems, especially where surface water and<space/><link><target>groundwater</target></link><space/>interactions occur. The use of phages is preferred to the more conventional<space/><link><target>dye</target></link><space/>marker because they are significantly less absorbed when passing through ground waters and they are readily detected at very low concentrations.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Martin<space/></arg><arg name="first1"><space/>C. 
</arg><arg name="doi"><space/>10.1111/j.1747-6593.1988.tb01352.x 
</arg><arg name="title"><space/>The Application of Bacteriophage Tracer Techniques in South West Water 
</arg><arg name="journal"><space/>Water and Environment Journal 
</arg><arg name="volume"><space/>2 
</arg><arg name="pages"><space/>638 
</arg><arg name="year"><space/>1988 
</arg><arg name="pmid"><space/>
</arg><arg name="pmc"><space/>
</arg></template></extension></paragraph><heading level='2'>Other areas of use</heading><paragraph>Since 2006, the<space/><link><target>United States Food and Drug Administration</target></link><space/>(FDA) and<space/><link><target>United States Department of Agriculture</target></link><space/>(USDA) have approved several bacteriophage products. LMP-102 (Intralytix) was approved for treating ready-to-eat (RTE) poultry and meat products. In that same year, the FDA approved LISTEX (developed and produced by<space/><link><target>Micreos (company)</target><part>Micreos</part></link>) using bacteriophages on cheese to kill<space/><italics><link><target>Listeria monocytogenes</target></link></italics><space/>bacteria, giving them<space/><link><target>generally recognized as safe</target></link><space/>(GRAS) status.<extension extension_name='ref'>U.S. FDA/CFSAN: Agency Response Letter, GRAS Notice No. 000198</extension><space/>In July 2007, the same bacteriophage were approved for use on all food products.<extension extension_name='ref'>(U.S. FDA/CFSAN: Agency Response Letter, GRAS Notice No. 000218)</extension><space/>In 2011 USDA confirmed that LISTEX is a clean label processing-aid and is included in USDA.<extension extension_name='ref'><link type='external' href='http://www.fsis.usda.gov/oppde/rdad/fsisdirectives/7120.1.pdf'>FSIS Directive 7120</link></extension><space/>Research in the field of food safety is continuing to see if lytic phages are a viable option to control other food-borne pathogens in various food products.</paragraph><paragraph>In 2011 the FDA cleared the first bacteriophage-based product for in vitro diagnostic use.<extension extension_name='ref'><link type='external' href='http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K102342'></link></extension><space/>The KeyPath MRSA/MSSA Blood Culture Test uses a cocktail of bacteriophage to detect<space/><italics><link><target>Staphylococcus aureus</target></link></italics><space/>in positive blood cultures and determine<space/><link><target>methicillin</target></link><space/>resistance or susceptibility. The test returns results in about 5 hours, compared to 23 days for standard microbial identification and susceptibility test methods. It was the first accelerated antibiotic susceptibility test approved by the FDA.<extension extension_name='ref'><link type='external' href='http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254512.htm'></link></extension></paragraph><paragraph>Government agencies in the West have for several years been looking to<space/><link><target>Georgia (country)</target><part>Georgia</part></link><space/>and the former<space/><link><target>Soviet Union</target></link><space/>for help with exploiting phages for counteracting bioweapons and toxins, such as<space/><link><target>anthrax</target></link><space/>and<space/><link><target>botulism</target></link>.<extension extension_name='ref'><link type='external' href='http://www.nytimes.com/2007/05/25/world/americas/25iht-institute.4.5869943.html'>The New York Times: Studying anthrax in a Soviet-era lab with Western funding</link></extension><space/>Developments are continuing among research groups in the US. Other uses include spray application in horticulture for protecting plants and vegetable produce from decay and the spread of bacterial disease. Other applications for bacteriophages are as biocides for environmental surfaces, e.g., in hospitals, and as preventative treatments for catheters and medical devices prior to use in clinical settings. The technology for phages to be applied to dry surfaces, e.g., uniforms, curtains, or even sutures for surgery now exists. Clinical trials reported in the<space/><italics>Lancet</italics><extension extension_name='ref' name="autogenerated2"><template><target>Cite journal</target><arg name="doi"><space/>10.1111/j.1749-4486.2009.01973.x</arg><arg name="pmid"><space/>19673983</arg><arg name="year"><space/>2009</arg><arg name="last1"><space/>Wright<space/></arg><arg name="first1"><space/>A.</arg><arg name="last2"><space/>Hawkins<space/></arg><arg name="first2"><space/>C.</arg><arg name="last3"><space/>Anggård<space/></arg><arg name="first3"><space/>E.</arg><arg name="last4"><space/>Harper<space/></arg><arg name="first4"><space/>D.</arg><arg name="title"><space/>A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy</arg><arg name="volume"><space/>34</arg><arg name="issue"><space/>4</arg><arg name="pages"><space/>349–357</arg><arg name="journal"><space/>Clinical Otolaryngology</arg></template></extension><space/>show success in veterinary treatment of pet dogs with otitis.</paragraph><paragraph><link><target>Phage display</target></link><space/>is a different use of phages involving a library of phages with a variable peptide linked to a surface protein. Each phage's genome encodes the variant of the protein displayed on its surface (hence the name), providing a link between the peptide variant and its encoding gene. Variant phages from the library can be selected through their binding affinity to an immobilized molecule (e.g., botulism toxin) to neutralize it. The bound, selected phages can be multiplied by reinfecting a susceptible bacterial strain, thus allowing them to retrieve the peptides encoded in them for further study.<template><target>citation needed</target><arg name="date">January 2012</arg></template></paragraph><paragraph>The<space/><link><target>Sensing of phage-triggered ion cascades (SEPTIC)</target><part>SEPTIC</part></link><space/>bacterium sensing and identification method uses the ion emission and its dynamics during phage infection and offers high specificity and speed for detection.<template><target>citation needed</target><arg name="date">January 2012</arg></template></paragraph><paragraph><link><target>Phage-ligand technology</target></link><space/>makes use of proteins, which are identified from bacteriophages, characterized and recombinantly expressed for various applications such as binding of bacteria and bacterial components (e.g.<space/><link><target>endotoxin</target></link>) and lysis of bacteria.<extension extension_name='ref'><link type='external' href='http://www.hyglos.de/en/technology/technological-background.html'>Technological background Phage-ligand technology</link></extension></paragraph><paragraph>Bacteriophages are also important<space/><link><target>model organisms</target></link><space/>for studying principles of<space/><link><target>evolution</target></link><space/>and<space/><link><target>ecology</target></link>.<extension extension_name='ref'><template><target>Cite journal</target><arg name="doi"><space/>10.4161/bact.28365
</arg><arg name="pmid"><space/>24616839
</arg><arg name="title"><space/>Tradeoffs in bacteriophage life histories
</arg><arg name="journal"><space/>Bacteriophage
</arg><arg name="volume"><space/>4
</arg><arg name="issue"><space/>1
</arg><arg name="pages"><space/>e28365
</arg><arg name="year"><space/>2014
</arg><arg name="last1"><space/>Keen<space/></arg><arg name="first1"><space/>E. C. 
</arg><arg name="pmc"><space/>3942329
</arg></template></extension></paragraph><heading level='2'>Model bacteriophages</heading><paragraph>The following bacteriophages are extensively studied:<template><target>colbegin</target><arg>3</arg></template></paragraph><list type='bullet'><listitem><link><target>Lambda phage</target><part>phage</part></link></listitem><listitem><link><target>T2 phage</target></link></listitem><listitem><link><target>T4 phage</target></link><space/>(169<space/><link><target>Base pair</target><part>kbp</part></link><space/>genome,<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Miller</arg><arg name="first">ES</arg><arg name="author2">Kutter, E</arg><arg name="author3">Mosig, G</arg><arg name="author4">Arisaka, F</arg><arg name="author5">Kunisawa, T</arg><arg name="author6">Rüger, W</arg><arg name="title">Bacteriophage T4 genome.</arg><arg name="journal">Microbiology and molecular biology reviews : MMBR</arg><arg name="date">March 2003</arg><arg name="volume">67</arg><arg name="issue">1</arg><arg name="pages">86–156, table of contents</arg><arg name="pmid">12626685</arg><arg name="doi">10.1128/MMBR.67.1.86-156.2003</arg><arg name="pmc">150520</arg></template></extension><space/>200<space/><link><target>nanometre</target><part>nm</part></link><space/>long<template><target>Citation needed</target><arg name="date">January 2010</arg></template>)</listitem><listitem><link><target>T7 phage</target></link></listitem><listitem><link><target>T12 phage</target></link></listitem><listitem><link><target>R17 phage</target></link></listitem><listitem><link><target>M13 phage</target></link></listitem><listitem><link><target>MS2 phage</target></link><space/>(2325<space/><link><target>nanometre</target><part>nm</part></link><space/>in size<template><target>Citation needed</target><arg name="date">January 2010</arg></template>)</listitem><listitem><link><target>G4 phage</target></link></listitem><listitem><link><target>P1 phage</target></link></listitem><listitem><link><target>Enterobacteria phage P2</target></link></listitem><listitem><link><target>P4 phage</target></link></listitem><listitem><link><target>Phi X 174</target></link><space/>phage</listitem><listitem><link><target>N4 phage</target></link></listitem><listitem><link><target>Pseudomonas phage 6</target></link></listitem><listitem><link><target>29 phage</target></link></listitem><listitem><link><target>186 phage</target></link></listitem></list><paragraph><template><target>colend</target></template></paragraph><heading level='2'>Cultural references</heading><list type='bullet'><listitem>In 1925 in the Pulitzer Prize-winning novel<space/><italics><link><target>Arrowsmith (novel)</target><part>Arrowsmith</part></link></italics>,<space/><link><target>Sinclair Lewis</target></link><space/>fictionalized the discovery and application of bacteriophages as a therapeutic agent.</listitem><listitem>The 1999<space/><link><target>Greg Bear</target></link><space/>novel<space/><italics><link><target>Darwin's Radio</target></link></italics><space/>deals with an epidemic in the form of long-dormant sections of human DNA, introduced in prehistoric times by lysogenic bacteriophages, which begin to express themselves. The sequel,<space/><italics><link><target>Darwin's Children</target></link></italics>, takes place in the post-epidemic world.</listitem></list><heading level='2'>See also</heading><paragraph><template><target>portal</target><arg>Viruses</arg></template></paragraph><list type='bullet'><listitem><link><target>Bacterivore</target></link></listitem><listitem><link><target>CrAssphage</target></link></listitem><listitem><link><target>DNA viruses</target></link></listitem><listitem><link><target>Phage ecology</target></link></listitem><listitem><link><target>Phage monographs</target></link><space/>(a comprehensive listing of phage and phage-associated monographs, 1921 present)</listitem><listitem><link><target>Polyphage</target></link></listitem><listitem><link><target>RNA viruses</target></link></listitem><listitem><link><target>Transduction (genetics)</target><part>Transduction</part></link></listitem><listitem><link><target>Viriome</target></link></listitem><listitem><link><target>CRISPR</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.egilsjolander.com/E_coli.mp4'>Animation of bacteriophage targeting E. coli bacteria</link></listitem><listitem><link type='external' href='http://www.bacteriophagetherapy.info/'>Husler, T. (2006) &quot;Viruses vs. Superbugs&quot;, Macmillan</link></listitem><listitem><link type='external' href='http://www.phage.org/'>Phage.org general information on bacteriophages</link></listitem><listitem><link type='external' href='http://bacteriophages.igmors.u-psud.fr/'>bacteriophages illustrations and genomics</link></listitem><listitem><link type='external' href='http://www.pdbe.org/quips?story=T4tail'>Bacteriophages get a foothold on their prey</link></listitem><listitem><link type='external' href='http://www.sciencefriday.com/program/archives/200804043'>NPR Science Friday podcast, &quot;Using 'Phage' Viruses to Help Fight Infection&quot;, April 2008</link></listitem><listitem><link type='external' href='http://www.hybridmedicalanimation.com/anim_bacteriophage.html'>Animation by ''Hybrid Animation Medical'' for a T4 Bacteriophage targeting ''E. coli'' bacteria.</link></listitem><listitem><template><target>YouTube</target><arg>3VjE1zddXWk</arg><arg>Bacteriophages: What are they. Presentation by Professor Graham Hatfull, University of Pittsburgh</arg></template></listitem></list><paragraph><template><target>modelling ecosystems</target></template><template><target>Virus topics</target></template></paragraph><paragraph><link><target>Category:Bacteriophages</target><part></part></link></paragraph></article>